← All trials
NCT00832234
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2006
- Primary completion
- Jun 1, 2010
- Completion date
- Jun 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 59
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- European Myeloma NetworkLead sponsor
- University of BarcelonaCollaborator
- University of AthensCollaborator
- University of AthensOverall official - principal investigator
- University of ToulouseCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Julius-Maximilians UniversityCollaborator
- University of PaviaCollaborator
- University of Roma La SapienzaCollaborator
- University of SalamancaCollaborator
- Centre Hospitalier de LensCollaborator
- Aristotle University of ThessalonikiCollaborator
- Lund UniversityCollaborator
- Aalborg UniversityCollaborator
- European Myeloma NetworkReponsible party - principal investigator
- University of GothenburgCollaborator
- University of TurinCollaborator
- Erasmus University RotterdamCollaborator
- University of MilanCollaborator
- University of ParisCollaborator
- Ludwig Maximilians UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.